Subscribe
shutterstock_1349383838_thomas_quack
Thomas Quack / Shutterstock.com
22 October 2019AmericasSarah Morgan

CRISPR Therapeutics to buy JV from Bayer

A joint venture between gene-editing startup CRISPR Therapeutics and German pharmaceutical company Bayer will come under the control of CRISPR Therapeutics, according to the pair’s proposed plans.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Bayer and CRISPR close joint venture transaction
19 August 2016   Bayer has launched a partnership with CRISPR Therapeutics.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

More on this story

Americas
Bayer and CRISPR close joint venture transaction
19 August 2016   Bayer has launched a partnership with CRISPR Therapeutics.

More on this story

Americas
Bayer and CRISPR close joint venture transaction
19 August 2016   Bayer has launched a partnership with CRISPR Therapeutics.

More features

As AI shakes up pharma and biotech, can patent law keep up?
UK court clears the way for Amgen and Samsung to launch biosimilars
SK Bioscience prevails over Pfizer in pneumococcal vaccine dispute
‘It’s going to be very different’: INTA CEO shares London meeting plans
'Scrap the billable hour': LSIPR joins INTA panel on gender diversity
Sanofi unit loses genetic disorder patent at EPO after trio of challenges
INTA confirms London as host city for Annual Meeting 2026
INTA unveils key principles on AI and IP rights at Annual Meeting